Cue Health
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Cue Health was a San Diego-based healthcare technology company founded in 2010 by Ayub Khattak and Clint Sever. It developed connected molecular diagnostic products for clinical and at-home use, anchored by the Cue Health Monitoring System. The company scaled rapidly during the pandemic on demand for its Cue COVID-19 test and went public on Nasdaq (ticker HLTH) in 2021, reaching a market valuation of about $3 billion.
02 / Cue Health FAILURE REASONS
Failure reasons
Cue's collapse was driven by the post-pandemic collapse in COVID-19 testing demand, on which the majority of its product revenue depended. The company burned cash in 2022 and 2023, failed to improve operational efficiency or repair its capital structure, and could not secure additional financing or a strategic transaction. An FDA warning letter over its emergency use authorization for a COVID-19 test added regulatory pressure, and its auditors flagged substantial doubt about the company's ability to continue as a going concern.
03 / EVENT HISTORY
Events in the structured record
- Liquidation
Cue Health Inc. 8-K signed 28 May 2024: voluntary liquidation bankruptcy in D. Del. (In re Cue Health Inc.); trustee to liquidate assets. Same 8-K: all employees/officers terminated as of 24 May 2024. Business Wire same day: 'filed voluntary petitions under liquidation bankruptcy ... to pursue a wind down.' Not bankruptcy restructuring.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
In May 2024, Cue Health filed voluntary Chapter 7 bankruptcy petitions in Delaware to wind down the business.
- 02
A bankruptcy trustee was appointed to gather and sell the company's assets and use proceeds to pay creditors.
- 03
In August 2024, Heritage Global Partners was appointed by the bankruptcy court to auction off more than 2,000 lots of assets, including lab equipment from the Carroll Canyon site and manufacturing assets from the Vista plant.
- 04
The company's audited 2023 10-K reported an accumulated deficit of $591.5 million as of December 31, 2023.
- 05
No shareholder recovery was expected from the Chapter 7 process.